eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
2/2005
vol. 1
 
Share:
Share:
more
 
 
abstract:

Case report
Effective combination of lamivudine with ursodeoxycholic acid in the treatment of acute flare of chronic hepatitis B infection after discontinuation of lamivudine therapy

Krisztina Hagymási
,
Gabriella Lengyel
,
Margit Horányi
,
Gábor Mester
,
János Fehér

Arch Med Sci 2005; 1, 2: 119-122
Online publish date: 2005/09/21
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Lamivudine is an effective nucleoside-analogue for the treatment of chronic hepatitis B. However, treatment withdrawal after 1 year has been associated with a high rate of relapse, while long-term treatment is associated with an increasing risk of drug resistance. The authors summarise the case of a 66-year old male with HBeAg-negative hepatitis B cirrhosis. With a 14-month lamivudine treatment (100 mg/day orally) only partial (biochemical) response was achieved. Serum HBV DNA sustained positive but the lamivudine treatment was stopped because it was not budgeted for. After 18 months of discontinuation of the lamivudin therapy – without any connection with the cessation of the nucleoside-analogue therapy – serious icteric flare of HBV cirrhosis occurred. Reinstitution of lamivudine completed with ursodeoxycholic acid resulted in virological and biochemical responses. In the future, a combination therapy for chronic HBV infection can be anticipated.
keywords:

lamivudine, ursodeoxycholic acid, combined treatment, HBeAg-negative chronic hepatitis B

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe